TP53 and cancer: Mechanistic investigations showed that (+)-strebloside mediates its potential antitumor activity by inhibition of Na+/K+-ATPase (NKA) and nuclear factor kappa B (NF-κB) activation, induction of cancer cell apoptosis, and inhibiting potently mutant p53 expression through the induction of the extracellular signal-regulated kinase (ERK) pathway [11], although it does not affect glucose transport in HT-29 human colon cancer cells [10].